The final balance of all these aspects of JAM-A functions may determine overall tumor progression; for example, positively regulate tumor progression in breast cancer [21], [22], [24] and NSCLC, or negatively regulate tumor progression in endometrial carcinoma [19] and pancreatic cancer [20]. This evidence concerns the gene F11R and endometrial carcinoma.